title: Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.
authors.forename: Ana
authors.initials: A
authors.lastname: Moreno
authors.forename: Carmen
authors.initials: C
authors.lastname: Quereda
authors.forename: Marisa
authors.initials: M
authors.lastname: Montes
authors.forename: María J
authors.initials: MJ
authors.lastname: Pérez-Elías
authors.forename: José L
authors.initials: JL
authors.lastname: Casado
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Rodríguez-Sagrado
authors.forename: María L
authors.initials: ML
authors.lastname: Mateos
authors.forename: Fernando
authors.initials: F
authors.lastname: Dronda
authors.forename: Rafael
authors.initials: R
authors.lastname: Bárcena
authors.forename: Santos
authors.initials: S
authors.lastname: Del Campo
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
mesh_terms: D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D060085:Coinfection / Q000188:drug therapy; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011392:Proline / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D019428:HIV Integrase Inhibitors; D017320:HIV Protease Inhibitors; D016898:Interferon-alpha; D009842:Oligopeptides; D011760:Pyrrolidinones; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D000068898:Raltegravir Potassium; D012254:Ribavirin; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline; C100416:peginterferon alfa-2a